The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.
Category: Regulation and Deregulation of Industry
-
F.D.A. Drug Unit Chief Is Placed on Leave, and Cites a ‘Toxic’ Environment
The official, Dr. George F. Tidmarsh, a top regulator at the agency, said disagreements over a new program to rapidly approve medications had caused tensions with agency officials.
-
Can Paul Atkins ‘Make I.P.O.s Great Again’?
The chair of the Securities and Exchange Commission has a plan to reverse the decline in public listings. His critics say he’s taking swings at the wrong target.
-
Fed Governor Defends Call for Big Rate Cuts
In a wide-ranging interview, Stephen I. Miran discussed why he thinks concerns about inflation are overblown and his worries about the economy if the Federal Reserve does not rapidly lower interest rates. Here is a full transcript.
-
How to Shop for Obamacare When Subsidies Are in Limbo
Enrollment for A.C.A. health coverage begins Nov. 1, with some staggering price increases. Here is a guide to help you choose a plan while Congress is at an impasse over tax credits.
-
Fed Risks a Recession if It Doesn’t Cut Rates Rapidly, Stephen Miran Warns
Stephen I. Miran, the newest member of the central bank’s Board of Governors, thinks some of his colleagues are too worried about inflation.
-
E.P.A. Retreats From Plans to End the Energy Star Program
The agency has faced blowback from business leaders and Republicans over plans to end the popular energy efficiency program.
-
Trump Administration Seeks to Return Medical Debt to Credit Reports
A federal rule restricting the debt’s inclusion has been canceled. Now, the consumer bureau is trying to overturn state restrictions.
-
F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may help lower drug costs.
-
What to know about the Fed meeting.
The U.S. central bank is widely expected to cut interest rates for the second meeting in a row even though the government shutdown is obscuring officials’ view of the economy.
-
What to Watch at the Federal Reserve’s October Meeting
The U.S. central bank is widely expected to cut interest rates for the second meeting in a row even though the government shutdown is obscuring officials’ view of the economy.